Ligand efficiency and fragment-based drug discovery
Authors:
- Scott D. BembenekSBScott D. Bembenek
- Brett A. ToungeBTBrett A. Tounge
- Charles H. ReynoldsCRCharles H. Reynolds
- 1 March 2009
- journal article
- review article
- Published by Elsevier in Drug Discovery Today
- Vol. 14 (5-6) , 278-283
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Ligand Binding Efficiency: Trends, Physical Basis, and ImplicationsJournal of Medicinal Chemistry, 2008
- The role of molecular size in ligand efficiencyBioorganic & Medicinal Chemistry Letters, 2007
- A decade of fragment-based drug design: strategic advances and lessons learnedNature Reviews Drug Discovery, 2007
- Virtual Exploration of the Chemical Universe up to 11 Atoms of C, N, O, F: Assembly of 26.4 Million Structures (110.9 Million Stereoisomers) and Analysis for New Ring Systems, Stereochemistry, Physicochemical Properties, Compound Classes, and Drug DiscoveryJournal of Chemical Information and Modeling, 2007
- Fragment-Based Drug Design: How Big Is Too Big?Journal of Medicinal Chemistry, 2006
- High-throughput drug discovery: What can we expect from HTS?Drug Discovery Today, 2005
- Ligand efficiency: a useful metric for lead selectionDrug Discovery Today, 2004
- Identification of “Latent Hits” in Compound Screening CollectionsJournal of Medicinal Chemistry, 2003
- Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug DiscoveryJournal of Chemical Information and Computer Sciences, 2001
- Discovering High-Affinity Ligands for Proteins: SAR by NMRScience, 1996